Takeda - TAK EV/Sales Multiple

Public company logo of takeda.com (TAK)

Takeda Pharmaceutical (TAK) faces a debt burden following the Shire acquisition and patent risks, further complicated by costly cold chain requirements for delivery. The firm's EV/Sales multiple reflects the impact of these factors, with the value holding at 3181.20. The implementation of robotic molecule screening and plant automation should stabilize the stock price in the future.

TAK Takeda EV/Sales Multiple (11/23/2025 - 11/20/2026)

Takeda Pharmaceutical Company - analytical breakdowns and key metrics (TAK)

- stock price and consensus target price:
Fundamental valuation:takeda.com TAK
Finished products of Takeda

Stable demand for Takeda Pharmaceutical (TAK) drugs for the treatment of rare diseases determines a steady trajectory for the company's enterprise value-to-revenue ratio. This metric compares the total Enterprise Value with annual turnover, neutralizing the impact of debt load to provide an objective valuation of the market price of one dollar of sales. Analyzing this ratio allows an investor to determine the degree of asset overvaluation relative to its ability to generate cash flow.